case_images: PMC8784387_01
case_images: Graphical timeline of case report with key oncologic, neurologic, and immunologic analyses and treatments. Color code for boxes: blue: oncologic history; red: treatments; light green: neurologic history; orange: immunologic analyses results. Every arrow indicates the duration of each treatment/immunologic situation. Dots represent specific key months. The scale is not strictly proportioned to dates.
case_images: fonc-11-799453-g001.jpg
case_images: PMC8784387_01_fonc-11-799453-g001.jpg
case_images: f1
case_images: A graphical representation of the case history is shown in  Figure 1 .
case_images: Radiological assessments. (A) March 2017 Head and neck contrast-enhanced magnetic resonance imaging:before the primary treatment. (B) November 2017 Head and neck contrast-enhanced magnetic resonance imaging of complete remission after chemoradiation. (C, D) March 2018 Whole body FDG PET:at diagnosis of metastatic disease. (E, F) November 2018 Whole body FDG PET of complete response after nivolumab.
case_images: fonc-11-799453-g002.jpg
case_images: PMC8784387_01_fonc-11-799453-g002.jpg
case_images: f2
case_images: Figure 2A ). Fine needle aspiration biopsy of the largest neck node (25 mm) demonstrated a poorly differentiated carcinoma, p16 immuno-histochemistry (IHC) positive in formalin-fixed, paraffin-embedded (FFPE) sections and HPV viral infection confirmed by in situ hybridization (ISH).